Cargando…

Telomerase activity in plasma cell dyscrasias

Activation of telomerase is essential for in vitro cellular immortalization and tumorigenesis. In the present study, we investigated telomerase activation and its implications in plasma cell dyscrasias including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, D, Zheng, C, Bergenbrant, S, Holm, G, Björkholm, M, Yi, Q, Gruber, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363791/ https://www.ncbi.nlm.nih.gov/pubmed/11237381 http://dx.doi.org/10.1054/bjoc.2000.1655

Ejemplares similares

Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms
por: Xu, D, et al.
Publicado: (1999)

Ocular complications of plasma cell dyscrasias
por: Singh, Rohan Bir, et al.
Publicado: (2023)

Mutational landscape reflects the biological continuum of plasma cell dyscrasias
por: Rossi, A, et al.
Publicado: (2017)

Quantitation of Monoclonal Plasma Cells in Bone Marrow Biopsies in Plasma Cell Dyscrasia
por: Markey, G. M., et al.
Publicado: (2003)

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
por: Morelli, Eugenio, et al.
Publicado: (2020)

Pus Dyscrasia
por: Barrett, W. C.
Publicado: (1881)

Crusted Scabies in Systemic Sclerosis with Plasma Cell Dyscrasia
por: Nikam, Balkrishna P., et al.
Publicado: (2018)

Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia
por: Rajapreyar, Indranee, et al.
Publicado: (2020)

Imaging for Plasma Cell Dyscrasias: What, When, and How?
por: Guha, Amrita, et al.
Publicado: (2022)

Opium Dyscrasia
por: Moore,
Publicado: (1886)

Detection of circulating carcinoma cells by telomerase activity
por: Gauthier, L R, et al.
Publicado: (2001)

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia
por: Golombick, Terry, et al.
Publicado: (2008)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

A case of plasma cell dyscrasia presenting as nonscarring alopecia
por: Nia, Benjamin, et al.
Publicado: (2021)

Clinical and Biological Characteristics of Medullary and Extramedullary Plasma Cell Dyscrasias
por: Janjetovic, Snjezana, et al.
Publicado: (2021)

Leptomeningeal isolated infiltration in plasma cell dyscrasia associated to HIV
por: Sprenger, Flávia, et al.
Publicado: (2022)

Diagnostic and Therapeutic Considerations in Concurrent Plasma Cell Dyscrasia and Amyloidosis
por: Baljevic, Muhamed
Publicado: (2022)

COVID-19 vaccine immune response and plasma cell dyscrasia
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Absence of telomerase activity and telomerase catalytic subunit mRNA in melanocyte cultures
por: Dhaene, K, et al.
Publicado: (2000)

Cutaneous Vasculitis: An Unusual Presentation of a Biclonal Nodal Plasma Cell Dyscrasia
por: Swan, D., et al.
Publicado: (2017)

Quantitative and qualitative assessment of plasma cell dyscrasias in dual-layer spectral CT
por: Brandelik, S. C., et al.
Publicado: (2021)

The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
por: Jasiński, Marcin, et al.
Publicado: (2021)

Telomerase reverse transcriptase and telomeric-repeat binding factor protein 1 as regulators of telomerase activity in pancreatic cancer cells
por: Yajima, T, et al.
Publicado: (2001)

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
por: Roccaro, Aldo M, et al.
Publicado: (2008)

Transient plasma cell dyscrasia in COVID-19 patients linked to IL-6 triggering
por: Farina, A., et al.
Publicado: (2021)

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
por: Zambello, Renato, et al.
Publicado: (2020)

Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study.
por: Danova, M., et al.
Publicado: (1990)

C-src Enriched Serum Microvesicles Are Generated in Malignant Plasma Cell Dyscrasia
por: Di Noto, Giuseppe, et al.
Publicado: (2013)

Value of PET-CT in plasma cell dyscrasias: a literature and pictorial review
por: Aggarwal, R, et al.
Publicado: (2015)

The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma
por: Xu, Yanjie, et al.
Publicado: (2023)

Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias
por: Rebmann Chigrinova, Ekaterina, et al.
Publicado: (2022)

Coexistence of Plasma Cell Dyscrasia with Prefibrotic Stage of Primary Myelofibrosis: A Case Report
por: Tsirakis, George, et al.
Publicado: (2011)

Post-Arsphenamine Blood Dyscrasias
por: Rajam, R. V., et al.
Publicado: (1938)

Telomerase activity in melanoma and non-melanoma skin cancer
por: Parris, C N, et al.
Publicado: (1999)

Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report
por: Zhang, Na, et al.
Publicado: (2022)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
por: Xu, Jinhuan, et al.
Publicado: (2018)

Telomerase activity and p53-dependent apoptosis in ovarian cancer cells
por: Akeshima, R, et al.
Publicado: (2001)

Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse
por: Remes, K, et al.
Publicado: (2000)

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias
por: Lionetti, Marta, et al.
Publicado: (2015)

The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications
por: Hemminki, Kari, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2mdnh1p2si801e84t4o58nfak7